Sep-04-20 Initiated H.C. Wainwright
Buy
$11
Aug-28-20 Initiated Wedbush
Outperform
$12
Sep-19-18 Initiated Robert W. Baird
Outperform
May-14-18 Initiated Goldman
Neutral
$17
May-14-18 Initiated Evercore ISI
Outperform
$26
May-16-21 06:20AM May-05-21 06:45AM Apr-28-21 04:05PM Apr-27-21 07:00AM Apr-19-21 07:00AM Apr-09-21 07:53AM Apr-08-21 07:32AM Mar-31-21 11:12AM Mar-30-21 06:11PM 04:30PM Mar-23-21 11:47PM Mar-18-21 08:00AM Mar-17-21 08:01AM Mar-10-21 04:35PM Mar-09-21 08:25AM 07:01AM 07:00AM 06:43AM Mar-05-21 08:48AM Mar-02-21 12:30PM Feb-24-21 07:00AM Feb-23-21 07:25AM Feb-22-21 06:21AM Feb-11-21 07:00AM Jan-19-21 03:25PM Jan-13-21 08:39AM Jan-11-21 06:00AM Dec-22-20 12:20PM 04:37AM Dec-17-20 03:35PM 08:10AM 06:55AM Dec-14-20 07:07AM Dec-07-20 08:29AM Nov-25-20 07:00AM Nov-15-20 08:39AM 06:57AM Nov-13-20 07:05AM Nov-11-20 07:00AM Nov-10-20 06:20AM Nov-09-20 04:25PM 09:00AM Nov-05-20 09:43AM Oct-26-20 04:05PM Oct-20-20 01:03PM Oct-19-20 12:32PM Oct-12-20 03:41PM Sep-16-20 05:05PM Sep-15-20 07:23AM Sep-11-20 03:00PM Sep-09-20 01:15PM Sep-04-20 09:38AM Sep-02-20 08:52AM Aug-28-20 10:16AM Aug-19-20 01:56PM Aug-11-20 06:30AM Aug-05-20 11:59AM Jun-12-20 09:45AM Jun-10-20 08:12PM May-28-20 04:10PM May-20-20 11:28AM 07:15AM 07:05AM May-15-20 11:46AM 07:30AM May-14-20 07:30AM May-13-20 08:00AM May-12-20 06:20AM May-07-20 12:30PM Apr-23-20 08:00AM Mar-17-20 08:00AM Mar-12-20 10:39AM Mar-10-20 06:20AM Mar-06-20 11:30AM Feb-25-20 04:05PM Feb-19-20 11:30AM Feb-04-20 06:58AM Jan-28-20 07:12AM Jan-27-20 04:05PM Dec-23-19 10:24AM Dec-09-19 05:45PM Nov-26-19 11:07AM 08:00AM Nov-25-19 08:00AM Nov-18-19 06:30AM Nov-12-19 07:45AM 06:30AM Nov-07-19 08:00AM Oct-26-19 06:25PM Oct-07-19 07:00AM Sep-23-19 12:50PM Sep-18-19 05:55PM Sep-17-19 05:25PM Lifshitz & Miller LLP Announces Investigation of Curaleaf Holdings, Inc., Granite Construction, Inc., Karyopharm Therapeutics, Inc., ProPetro Holdings Corp., SAExploration, Inc., Sunnova Energy International, Inc., and Surface Oncology, Inc. PR Newswire -8.48%
Sep-03-19 04:05PM 01:45PM 07:00AM Aug-28-19 10:45AM Aug-27-19 08:00AM Aug-21-19 08:45PM Aug-20-19 01:15PM
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROSS ROBERT W. Chief Medical Officer Feb 16 Sale 11.35 1,000 11,350 88,000 Feb 18 08:00 PM Goater Jeff Chief Executive Officer Feb 08 Option Exercise 3.18 2,500 7,950 264,500 Feb 09 08:00 PM FEES JESSICA See Remarks Feb 08 Sale 12.45 1,500 18,675 99,183 Feb 09 08:00 PM Goater Jeff Chief Executive Officer Feb 08 Sale 12.50 2,500 31,250 262,000 Feb 09 08:00 PM Goater Jeff Chief Executive Officer Feb 01 Option Exercise 3.18 2,500 7,950 264,500 Feb 03 08:00 PM FEES JESSICA See Remarks Feb 01 Sale 11.19 1,500 16,785 100,683 Feb 03 08:00 PM Goater Jeff Chief Executive Officer Feb 01 Sale 10.69 2,500 26,718 262,000 Feb 03 08:00 PM Goater Jeff Chief Executive Officer Jan 19 Option Exercise 3.18 5,000 15,900 267,000 Jan 21 08:17 PM Goater Jeff Chief Executive Officer Jan 19 Sale 13.00 5,000 65,000 262,000 Jan 21 08:17 PM ROSS ROBERT W. Chief Medical Officer Jan 15 Sale 12.25 2,000 24,500 89,000 Jan 15 08:00 PM ROSS ROBERT W. Chief Medical Officer Jan 14 Sale 11.95 7,000 83,650 91,000 Jan 15 08:00 PM Atlas Venture Fund IX, L.P. 10% Owner Dec 17 Sale 18.10 1,700,000 30,770,000 2,945,453 Dec 21 01:32 PM GRAYZEL DAVID S. Director Dec 17 Sale 18.10 1,700,000 30,770,000 2,945,453 Dec 21 01:32 PM ROSS ROBERT W. Chief Medical Officer Dec 15 Sale 10.48 1,000 10,480 98,000 Dec 17 08:00 PM ROSS ROBERT W. Chief Medical Officer Dec 11 Sale 10.05 1,405 14,120 99,000 Dec 15 08:00 PM FEES JESSICA See Remarks Nov 25 Option Exercise 5.06 1,383 6,996 102,183 Nov 27 08:00 PM ROSS ROBERT W. Chief Medical Officer Nov 11 Sale 10.05 595 5,980 100,405 Nov 13 08:00 PM FEES JESSICA See Remarks Oct 28 Option Exercise 4.14 4,895 20,262 100,800 Oct 30 08:30 PM ROSS ROBERT W. Chief Medical Officer Oct 14 Sale 10.05 4,000 40,200 101,000 Oct 16 08:02 PM EcoR1 Capital, LLC 10% Owner Sep 01 Sale 7.14 332,780 2,376,681 4,701,081 Sep 03 04:17 PM New Enterprise Associates 14, 10% Owner May 20 Sale 3.66 420,000 1,535,562 2,892,877 May 22 04:56 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
